This enrichment of TP53 mutations in the metastasis samples, which appear at low frequency in primary samples, strongly suggests that the acquisition of TP53 mutations in the prostate cancer setting enhances the metastatic potential of tumour subclones. This evidence concerns the gene TP53 and prostate carcinoma.